• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Gritstone bio Inc. (Amendment)

    2/10/23 1:48:41 PM ET
    $GRTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $GRTS alert in real time by email
    SC 13G/A 1 grts13ga.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. 2)

    Gritstone bio, Inc.

    (Name of Issuer)

    Common Stock, $0.0001 par value

    (Title of Class of Securities)

    39868T105

    (CUSIP Number)

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X]       Rule 13d-1(b)

    [X]       Rule 13d-1(c)

    [ ]       Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     1 
    CUSIP No. 39868T105

     

     

    1.Names of Reporting Persons.

    EcoR1 Capital, LLC

     

    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) X

    (b)

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power 0
    6. Shared Voting Power 0
    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 0

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 0

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 0%

     

    12.Type of Reporting Person (See Instructions) OO, IA

     

     2 
    CUSIP No. 39868T105

     

     

    1.Names of Reporting Persons.

    Oleg Nodelman

     

    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) X

    (b)

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization United States

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power 0
    6. Shared Voting Power 0
    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 0

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 0

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 0%

     

    12.Type of Reporting Person (See Instructions) IN, HC

     

     3 
    CUSIP No. 39868T105

     

     

    1.Names of Reporting Persons.

    EcoR1 Capital Fund Qualified, L.P.

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) ______

     

    3. SEC Use Only

     

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 0
    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 0

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 0

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 0%

     

    12.Type of Reporting Person (See Instructions) PN

     

     

     4 
    CUSIP No. 39868T105

     

     

    Item1.
    (a)Name of Issuer

    Gritstone bio, Inc.

     

    (b)Address of Issuer’s Principal Executive Offices

    5959 Horton Street, Suite 300, Emeryville, California 94608

    ________________________________________________________________________

    Item2.
    (a)The names of the persons filing this statement are:

    EcoR1 Capital Fund Qualified, L.P. (“Qualified Fund”); EcoR1 Capital, LLC (“EcoR1”) and Oleg Nodelman (“Nodelman”) (collectively, the “Filers”).

     

    Qualified Fund is filing this statement jointly with the other Filers, but not as a member of a group and it expressly disclaims membership in a group. In addition, filing this Schedule 13G on behalf of Qualified Fund should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any of the Stock covered by this Schedule 13G.

     

    Each Filer also disclaims beneficial ownership of the Stock except to the extent of that person’s pecuniary interest therein.

     

    (b)The principal business office of the Filers is located at:

    357 Tehama Street #3, San Francisco, CA 94103

     

    (c)For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

     

    (d)This statement relates to the Issuer’s shares of Common Stock, $0.0001 par value (the “Stock”).

     

    (e)The CUSIP number of the Issuer is: 39868T105.
     5 
    CUSIP No. 39868T105

     

    Item 3.If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b)[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d)[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e)[ X ] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E) as to EcoR1.
    (f)[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).
    (g)[ X ] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G)
    as to Mr. Nodelman.
    (h)[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
    (i)[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
    (j)[ ] Group, in accordance with section 240.13d-1(b)(1)(ii)(J).
    Item 4.Ownership.

    See Items 5-9 and 11 of the cover page for each Filer.

    Item 5.Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ X ].

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

    The funds managed by EcoR1, including Qualified Fund, hold the Stock for the benefit of their investors and have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Stock.

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not applicable.

    Item 8.Identification and Classification of Members of the Group.

    EcoR1 is the general partner and investment adviser of investment funds, including Qualified Fund. Mr. Nodelman is the control person of EcoR1.

     

    Item 9.Notice of Dissolution of Group.

    Not applicable.

    Item 10.Certification.

    Certification of EcoR1 and Mr. Nodelman:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    Certification of Qualified Fund:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 10, 2023

     

    EcoR1 CAPITAL, LLC

     

     

    By:/s/ Oleg Nodelman

    Oleg Nodelman, Manager

     

     

     

     

     

    /s/ Oleg Nodelman
    Oleg Nodelman

    EcoR1 CAPITAL FUND QUALIFIED, L.P.

     

    By: EcoR1 Capital, LLC, General Partner

     

     

    By:/s/ Oleg Nodelman

    Oleg Nodelman, Manager

     

     
     6 
    CUSIP No. 39868T105

    EXHIBIT A

    AGREEMENT REGARDING JOINT FILING
    OF STATEMENT ON SCHEDULE 13D OR 13G

    The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D, Schedule 13G or Forms 3, 4 or 5 (and any amendments or supplements thereto) required under section 13(d) or 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned hereby constitute and appoint EcoR1 Capital, LLC a Delaware limited liability company, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

    Dated: February 10, 2023

    EcoR1 CAPITAL, LLC

     

     

    By:/s/ Oleg Nodelman

    Oleg Nodelman, Manager

     

     

     

     

     

    /s/ Oleg Nodelman
    Oleg Nodelman

    EcoR1 CAPITAL FUND QUALIFIED, L.P.

     

    By: EcoR1 Capital, LLC, General Partner

     

     

    By:/s/ Oleg Nodelman

    Oleg Nodelman, Manager

     

     

    08689\007\9421535.v1

    Get the next $GRTS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GRTS

    DatePrice TargetRatingAnalyst
    10/1/2024Mkt Outperform → Mkt Perform
    JMP Securities
    2/28/2024$4.00Mkt Outperform
    JMP Securities
    3/31/2023Outperform
    Evercore ISI
    3/28/2023$8.00Buy
    B. Riley Securities
    10/31/2022$6.00Overweight
    Piper Sandler
    8/22/2022$2.00Neutral → Sell
    Goldman
    12/15/2021$15.00Neutral
    Goldman
    10/15/2021$20.00Buy
    BTIG Research
    More analyst ratings

    $GRTS
    SEC Filings

    View All

    Gritstone bio Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities

    8-K - Gritstone bio, Inc. (0001656634) (Filer)

    10/16/24 4:06:00 PM ET
    $GRTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gritstone bio Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Regulation FD Disclosure

    8-K - Gritstone bio, Inc. (0001656634) (Filer)

    10/10/24 8:29:59 AM ET
    $GRTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 8-K filed by Gritstone bio Inc.

    8-K - Gritstone bio, Inc. (0001656634) (Filer)

    9/30/24 8:05:58 PM ET
    $GRTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GRTS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Gritstone bio Takes Action to Preserve Value and Strengthen Capital Structure

    Voluntarily Files for Chapter 11 Restructuring Strategic Alternatives Process Continues with Interest from Parties Gritstone bio, Inc. (NASDAQ:GRTS) ("Gritstone" or the "Company"), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced it has filed a voluntary petition under chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware. Gritstone intends to use the court-administered restructuring process to preserve value and support its ongoing strategic alternatives process. The Company is in discussions with a party to act as a stalking horse bidder or plan sponsor and intends to

    10/10/24 5:50:00 AM ET
    $GRTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gritstone bio Announces Interim Phase 2 Data for GRANITE Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer

    --Encouraging progression-free survival data in overall population; continued follow-up needed to allow data to mature further, especially in low ctDNA subgroup where events accrue more slowly --21% relative risk reduction of progression or death with GRANITE vs. control in all treated population (HR=0.79 [95% CI, 0.42-1.50])-- -- 38% relative risk reduction of progression or death with GRANITE vs. control in low ctDNA subgroup (HR=0.62 [95% CI, 0.23-1.70]) -- -- Strength of neoantigen specific T cell responses in GRANITE patients appears to associate with progression-free survival -- GRANITE was generally well-tolerated with no treatment discontinuations due to adverse events– -- Overa

    9/30/24 4:05:00 PM ET
    $GRTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gritstone bio Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

    -- Preliminary randomized Phase 2 data suggest GRANITE (personalized neoantigen vaccine) could drive meaningful clinical benefit in front-line metastatic microsatellite-stable colorectal cancer (MSS-CRC); mature progression-free survival (PFS) data expected in the third quarter of 2024 -- -- Recent KOL event and patient advocacy engagements underscore the unmet need for new treatment options in metastatic colorectal cancer -- -- Presentations at AACR 2024 and ESCMID Global 2024 demonstrate the broad potential of Gritstone's oncology and infectious disease vaccines -- -- Cash, cash equivalents, marketable securities and restricted cash of $61.7 million as of June 30, 2024 -- EMERYVILLE, C

    8/13/24 4:05:00 PM ET
    $GRTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GRTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT AND CEO Allen Andrew R gifted 650,000 shares, decreasing direct ownership by 25% to 985,360 units (SEC Form 4)

    4 - Gritstone bio, Inc. (0001656634) (Issuer)

    6/26/24 9:25:58 PM ET
    $GRTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Fisher Clare

    4 - Gritstone bio, Inc. (0001656634) (Issuer)

    6/20/24 6:23:33 PM ET
    $GRTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Agarwal Shefali

    4 - Gritstone bio, Inc. (0001656634) (Issuer)

    6/20/24 6:19:11 PM ET
    $GRTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GRTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Gritstone bio downgraded by JMP Securities

    JMP Securities downgraded Gritstone bio from Mkt Outperform to Mkt Perform

    10/1/24 7:33:47 AM ET
    $GRTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    JMP Securities initiated coverage on Gritstone bio with a new price target

    JMP Securities initiated coverage of Gritstone bio with a rating of Mkt Outperform and set a new price target of $4.00

    2/28/24 6:17:40 AM ET
    $GRTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Evercore ISI initiated coverage on Gritstone bio

    Evercore ISI initiated coverage of Gritstone bio with a rating of Outperform

    3/31/23 8:59:35 AM ET
    $GRTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GRTS
    Leadership Updates

    Live Leadership Updates

    View All

    Gritstone bio Announces Appointment of Stephen Webster to its Board of Directors

    EMERYVILLE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced the appointment of Stephen Webster to its Board of Directors. A veteran finance executive in the biotechnology industry, Mr. Webster has served as an executive for several renowned companies and held key roles in raising capital, business development transactions and operations for over 30 years. The company also announced that Steve Krognes will not stand for re-election at the 2024 Annual Meeting. "We are excited to welcome Stephen Webster to our Board of Directors at this important and excit

    4/29/24 7:00:00 AM ET
    $GRTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gritstone bio Presents Improvements to EDGE™ Platform at AACR 2024

    -- State-of-the-art neoantigen prediction platform (EDGE™) now predicts HLA Class I presentation of epitopes with >80% accuracy -- -- Newly developed EDGE-II model achieves superior predictive performance of HLA Class II presentation and CD4+ immunogenicity over publicly available models -- -- Combined with Gritstone's vaccine vectors, EDGE has demonstrated best-in-class potential in identifying neoantigens capable of eliciting T cell immune responses for robust and durable immunity -- EMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today presented an upd

    4/8/24 7:00:00 AM ET
    $GRTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Predictive Oncology Appoints Leading Biopharma Executive Matthew J. Hawryluk Ph.D. to the Board of Directors

    EAGAN, Minn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI) is pleased to announce the appointment of Matthew J. Hawryluk, Ph.D., (www.predictive-oncology.com) to its Board of Directors to help support the company's strategic initiatives and commercialization efforts. Dr. Hawryluk currently serves as Executive Vice President and Chief Business Officer of Gritstone bio, Inc (NASDAQ:GRTS). Recognized by Pharmaceutical Executive magazine as a leading business executive in the pharma and biotech industries, Dr. Hawryluk has played key roles in bridging the gap between scientific discovery and the commercial application of scientific breakthroughs. As a named invento

    12/5/22 8:30:00 AM ET
    $GRTS
    $POAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Industrial Specialties

    $GRTS
    Financials

    Live finance-specific insights

    View All

    Gritstone bio to Report First Quarter 2024 Financial Results and Provide Corporate Updates on May 9, 2024

    -- Conference call and webcast to begin at 4:30pm ET -- EMERYVILLE, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced it will report financial results for the first quarter 2024 and provide corporate updates after market close on Thursday, May 9, 2024. The announcement will be followed by a conference call and audio webcast, which will begin at 4:30pm ET. To access by phone, dial: 1-877-407-4018Conference ID: 13746126To access by webcast, visit: https://viavid.webcasts.com/starthere.jsp?ei=1667088&tp_key=d0e680f7aa While not required, it is recommended yo

    5/2/24 4:05:00 PM ET
    $GRTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gritstone bio Reports First Quarter 2023 Financial Results and Provides Corporate Updates

    -- Robust enrollment in Phase 2 portion of randomized Phase 2/3 study of GRANITE (personalized vaccine in first-line metastatic microsatellite-stable colorectal cancer [MSS-CRC]) to date; 71 of 80 patients (initial target) enrolled as of May 10, 2023 -- -- Gritstone prioritizing GRANITE; expanding Phase 2 from 80 to 100 patients, enrollment completion expected in 3Q2023, preliminary data on approximately 50 patients expected in 1Q2024 -- -- Cash, cash equivalents, marketable securities, and restricted cash of $153.2 million as of March 31, 2023 -- -- Gritstone to host conference call today at 4:30pm ET -- EMERYVILLE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ

    5/11/23 4:05:00 PM ET
    $GRTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gritstone bio to Report First Quarter 2023 Financial Results and Provide Corporate Update on May 11, 2023

    EMERYVILLE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced it will report its first quarter 2023 financial results and provide a corporate update following market close on Thursday, May 11, 2023. The announcement will be followed by a conference call and audio webcast, which will begin at 4:30pm ET. Live Conference Call & WebcastToll Free: 1-888-999-6281International: 1-848-280-6550Conference ID: 1754341Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1612896&tp_key=c6c637ac24 While not required, it is recommended you join five minutes prior to the

    5/3/23 7:00:00 AM ET
    $GRTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GRTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Gritstone bio Inc.

    SC 13G/A - Gritstone bio, Inc. (0001656634) (Subject)

    11/6/24 5:34:44 PM ET
    $GRTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Gritstone bio Inc.

    SC 13G - Gritstone bio, Inc. (0001656634) (Subject)

    10/7/24 5:01:07 PM ET
    $GRTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Gritstone bio Inc.

    SC 13G/A - Gritstone bio, Inc. (0001656634) (Subject)

    7/8/24 4:32:39 PM ET
    $GRTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care